The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.

MLA

Lutfi, Forat, et al. “The Impact of Bridging Therapy Prior to CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma.” British Journal of Haematology, vol. 195, no. 3, Nov. 2021, pp. 405–12. EBSCOhost, https://doi.org/10.1111/bjh.17738.

APA

Lutfi, F., Holtzman, N. G., Kansagra, A. J., Mustafa Ali, M., Bukhari, A., Yan, J., Samanta, S., Gottlieb, D., Kim, D. W., Matsumoto, L. R., Gahres, N., Ruehle, K., Lee, S. T., Law, J. Y., Kocoglu, M. H., Atanackovic, D., Yared, J. A., Hardy, N. M., Molitoris, J., … Dahiya, S. (2021). The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma. British Journal of Haematology, 195(3), 405–412. https://doi.org/10.1111/bjh.17738

Chicago

Lutfi, Forat, Noa G Holtzman, Ankit J Kansagra, Moaath Mustafa Ali, Ali Bukhari, Jingsheng Yan, Santanu Samanta, et al. 2021. “The Impact of Bridging Therapy Prior to CD19-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma.” British Journal of Haematology 195 (3): 405–12. doi:10.1111/bjh.17738.